Research ExplorerPublicationsGeneration of high-titre virus stocks using BrK.219, a B-cel...

Generation of high-titre virus stocks using BrK.219, a B-cell line infected stably with recombinant Kaposi's sarcoma-associated herpesvirus

Standard

Generation of high-titre virus stocks using BrK.219, a B-cell line infected stably with recombinant Kaposi's sarcoma-associated herpesvirus. / Kati, Semra; Hage, Elias; Mynarek, Martin; Ganzenmueller, Tina; Indenbirken, Daniela; Grundhoff, Adam; Schulz, Thomas F.

In: J VIROL METHODS, Vol. 217, 01.06.2015, p. 79-86.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kati, S, Hage, E, Mynarek, M, Ganzenmueller, T, Indenbirken, D, Grundhoff, A & Schulz, TF 2015, 'Generation of high-titre virus stocks using BrK.219, a B-cell line infected stably with recombinant Kaposi's sarcoma-associated herpesvirus', J VIROL METHODS, vol. 217, pp. 79-86. https://doi.org/10.1016/j.jviromet.2015.02.022

APA

Kati, S., Hage, E., Mynarek, M., Ganzenmueller, T., Indenbirken, D., Grundhoff, A., & Schulz, T. F. (2015). Generation of high-titre virus stocks using BrK.219, a B-cell line infected stably with recombinant Kaposi's sarcoma-associated herpesvirus. J VIROL METHODS, 217, 79-86. https://doi.org/10.1016/j.jviromet.2015.02.022

Vancouver

Kati S, Hage E, Mynarek M, Ganzenmueller T, Indenbirken D, Grundhoff A et al. Generation of high-titre virus stocks using BrK.219, a B-cell line infected stably with recombinant Kaposi's sarcoma-associated herpesvirus. J VIROL METHODS. 2015 Jun 1;217:79-86. https://doi.org/10.1016/j.jviromet.2015.02.022

Bibtex

@article{d7cf2febf96f45249c264b1c6c026e5a,
title = "Generation of high-titre virus stocks using BrK.219, a B-cell line infected stably with recombinant Kaposi's sarcoma-associated herpesvirus",
abstract = "Kaposi's sarcoma-associated herpesvirus (KSHV) is a gamma-2-lymphotropic human oncogenic herpesvirus associated with Kaposi's sarcoma (KS) and two B-cell lymphoproliferative diseases, primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD). KSHV establishes latency soon after infection in vivo and in vitro. Consequently, it is technically difficult to generate high-titre virus stocks required for infection experiments in tissue culture. Currently used methods of KSHV stock production involve induction of the lytic/productive cycle in PEL cell lines or in adherent cell lines harbouring recombinant KSHV genomes. In this study, the BJAB-derived B-cell line BrK.219, which is infected latently with a recombinant KSHV (rKSHV.219), is used to produce high-titre virus stocks. BrK.219 cells enter the lytic KSHV replication cycle upon cross-linking of B-cell receptors (BCRs) with anti-IgM antibodies without the need for additional, potentially toxic chemical inducers. High cell concentrations can be cultured and induced easily in spinner flasks, saving time and resources. The established protocol allows the generation of KSHV virus stocks with titres of up to 10(6)IU/ml in unconcentrated culture supernatants, representing a 10(3)-10(4)-fold improvement compared to conventional methods.",
author = "Semra Kati and Elias Hage and Martin Mynarek and Tina Ganzenmueller and Daniela Indenbirken and Adam Grundhoff and Schulz, {Thomas F}",
note = "Copyright {\textcopyright} 2015 Elsevier B.V. All rights reserved.",
year = "2015",
month = jun,
day = "1",
doi = "10.1016/j.jviromet.2015.02.022",
language = "English",
volume = "217",
pages = "79--86",
journal = "J VIROL METHODS",
issn = "0166-0934",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Generation of high-titre virus stocks using BrK.219, a B-cell line infected stably with recombinant Kaposi's sarcoma-associated herpesvirus

AU - Kati, Semra

AU - Hage, Elias

AU - Mynarek, Martin

AU - Ganzenmueller, Tina

AU - Indenbirken, Daniela

AU - Grundhoff, Adam

AU - Schulz, Thomas F

N1 - Copyright © 2015 Elsevier B.V. All rights reserved.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Kaposi's sarcoma-associated herpesvirus (KSHV) is a gamma-2-lymphotropic human oncogenic herpesvirus associated with Kaposi's sarcoma (KS) and two B-cell lymphoproliferative diseases, primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD). KSHV establishes latency soon after infection in vivo and in vitro. Consequently, it is technically difficult to generate high-titre virus stocks required for infection experiments in tissue culture. Currently used methods of KSHV stock production involve induction of the lytic/productive cycle in PEL cell lines or in adherent cell lines harbouring recombinant KSHV genomes. In this study, the BJAB-derived B-cell line BrK.219, which is infected latently with a recombinant KSHV (rKSHV.219), is used to produce high-titre virus stocks. BrK.219 cells enter the lytic KSHV replication cycle upon cross-linking of B-cell receptors (BCRs) with anti-IgM antibodies without the need for additional, potentially toxic chemical inducers. High cell concentrations can be cultured and induced easily in spinner flasks, saving time and resources. The established protocol allows the generation of KSHV virus stocks with titres of up to 10(6)IU/ml in unconcentrated culture supernatants, representing a 10(3)-10(4)-fold improvement compared to conventional methods.

AB - Kaposi's sarcoma-associated herpesvirus (KSHV) is a gamma-2-lymphotropic human oncogenic herpesvirus associated with Kaposi's sarcoma (KS) and two B-cell lymphoproliferative diseases, primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD). KSHV establishes latency soon after infection in vivo and in vitro. Consequently, it is technically difficult to generate high-titre virus stocks required for infection experiments in tissue culture. Currently used methods of KSHV stock production involve induction of the lytic/productive cycle in PEL cell lines or in adherent cell lines harbouring recombinant KSHV genomes. In this study, the BJAB-derived B-cell line BrK.219, which is infected latently with a recombinant KSHV (rKSHV.219), is used to produce high-titre virus stocks. BrK.219 cells enter the lytic KSHV replication cycle upon cross-linking of B-cell receptors (BCRs) with anti-IgM antibodies without the need for additional, potentially toxic chemical inducers. High cell concentrations can be cultured and induced easily in spinner flasks, saving time and resources. The established protocol allows the generation of KSHV virus stocks with titres of up to 10(6)IU/ml in unconcentrated culture supernatants, representing a 10(3)-10(4)-fold improvement compared to conventional methods.

U2 - 10.1016/j.jviromet.2015.02.022

DO - 10.1016/j.jviromet.2015.02.022

M3 - SCORING: Journal article

C2 - 25736227

VL - 217

SP - 79

EP - 86

JO - J VIROL METHODS

JF - J VIROL METHODS

SN - 0166-0934

ER -